Hybio Pharmaceutical Working Capital to Net Assets Ratio
Hybio Pharmaceutical working capital to net assets ratio. Hybio Pharmaceutical (300199) has a Working Capital to Net Assets ratio of -142.9% as of September 2025. Working capital of CN¥-951.59 Million (current assets of CN¥565.09 Million minus current liabilities of CN¥1.52 Billion) is measured against net assets of CN¥666.08 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Hybio Pharmaceutical (2007–2024)
Working capital to net assets ratio of Hybio Pharmaceutical from 2007 to 2024. This chart shows how Hybio Pharmaceutical's Working Capital to Net Assets ratio has evolved across 18 annual periods from 2007 to 2024. As of September 2025, the ratio stands at -142.9%, reflecting working capital of CN¥-951.59 Million against net assets of CN¥666.08 Million CNY. Explore 300199 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Hybio Pharmaceutical Working Capital to Net Assets Ratio by Year (2007–2024)
Hybio Pharmaceutical working capital to net assets ratio by year from 2007 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Hybio Pharmaceutical from 2007 to 2024, covering 18 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see how large is Hybio Pharmaceutical's balance sheet.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -161.0% | CN¥-961.51 Million | CN¥597.05 Million | CN¥463.05 Million | CN¥1.42 Billion | ▼ -66.6 pp |
| 2023 | -94.5% | CN¥-739.80 Million | CN¥783.21 Million | CN¥683.64 Million | CN¥1.42 Billion | ▼ -68.6 pp |
| 2022 | -25.9% | CN¥-335.63 Million | CN¥1.30 Billion | CN¥812.32 Million | CN¥1.15 Billion | ▼ -50.8 pp |
| 2021 | 25.0% | CN¥411.26 Million | CN¥1.65 Billion | CN¥1.16 Billion | CN¥743.82 Million | ▲ +27.9 pp |
| 2020 | -3.0% | CN¥-49.98 Million | CN¥1.68 Billion | CN¥1.05 Billion | CN¥1.10 Billion | ▼ -36.9 pp |
| 2019 | 33.9% | CN¥757.06 Million | CN¥2.23 Billion | CN¥1.89 Billion | CN¥1.14 Billion | ▼ -30.7 pp |
| 2018 | 64.6% | CN¥2.19 Billion | CN¥3.39 Billion | CN¥3.02 Billion | CN¥831.93 Million | ▲ +19.9 pp |
| 2017 | 44.6% | CN¥1.73 Billion | CN¥3.88 Billion | CN¥2.60 Billion | CN¥865.01 Million | ▲ +2.7 pp |
| 2016 | 41.9% | CN¥1.51 Billion | CN¥3.60 Billion | CN¥1.84 Billion | CN¥330.92 Million | ▲ +20.7 pp |
| 2015 | 21.2% | CN¥560.29 Million | CN¥2.64 Billion | CN¥979.38 Million | CN¥419.09 Million | ▼ -46.1 pp |
| 2014 | 67.3% | CN¥872.52 Million | CN¥1.30 Billion | CN¥990.66 Million | CN¥118.14 Million | ▲ +14.8 pp |
| 2013 | 52.6% | CN¥590.81 Million | CN¥1.12 Billion | CN¥667.20 Million | CN¥76.39 Million | ▼ -20.3 pp |
| 2012 | 72.9% | CN¥740.44 Million | CN¥1.02 Billion | CN¥789.94 Million | CN¥49.50 Million | ▼ -19.1 pp |
| 2011 | 92.0% | CN¥898.16 Million | CN¥976.09 Million | CN¥927.75 Million | CN¥29.59 Million | ▲ +27.0 pp |
| 2010 | 65.0% | CN¥117.40 Million | CN¥180.59 Million | CN¥133.10 Million | CN¥15.71 Million | ▲ +19.4 pp |
| 2009 | 45.6% | CN¥58.31 Million | CN¥127.74 Million | CN¥112.62 Million | CN¥54.31 Million | ▲ +13.1 pp |
| 2008 | 32.5% | CN¥32.30 Million | CN¥99.23 Million | CN¥69.41 Million | CN¥37.11 Million | ▼ -24.5 pp |
| 2007 | 57.1% | CN¥27.79 Million | CN¥48.70 Million | CN¥37.34 Million | CN¥9.54 Million | — |